Mixtard 30 Innolet (Insulin Human)

Insulin Human, the active ingredient in Mixtard 30 Innolet, is an insulin presented as a premixed insulin suspension for subcutaneous injection use. It lowers blood glucose by facilitating cellular uptake and suppressing hepatic glucose production, and is indicated for the management of type 1 and type 2 diabetes mellitus.

GNH USA supplies Mixtard 30 Innolet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for importers globally.

Mixtard 30 Innolet is a premixed insulin used in the management of diabetes mellitus, a disorder of glucose regulation.

- Type 1 diabetes mellitus: provides basal and prandial insulin to achieve glycemic control. - Type 2 diabetes mellitus: supplements oral agents or diet/exercise when additional glucose lowering is required. - Acute hyperglycemia: rapidly reduces elevated blood glucose during uncontrolled diabetic episodes.

Mixtard 30 Innolet may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Hypoglycemia: symptoms of low blood sugar such as sweating, tremor, or confusion. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: modest increase in body weight due to improved glucose utilization. - Lipodystrophy: localized changes in subcutaneous fat with repeated injections.

Serious or Rare Side Effects: - Severe hypoglycemia: can lead to loss of consciousness or seizures. - Allergic reactions: including rash, urticaria, or anaphylaxis. - Insulin edema: fluid retention causing swelling, particularly in the lower extremities.

When using Mixtard 30 Innolet, several precautions should be observed to ensure safe and effective therapy.

- Dose adjustment: tailor the dose based on regular blood glucose monitoring and individual response. - Hypoglycemia risk: educate patients on early signs and appropriate treatment measures. - Renal impairment: monitor renal function closely as insulin clearance may be reduced. - Pregnancy: consider use only if the potential benefit outweighs the potential risk to the fetus. - Drug interactions: review all concomitant medications for possible additive glucose‑lowering effects. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Mixtard 30 Innolet can interact with other medicines, altering its glucose‑lowering effect or masking symptoms.

Major Interactions (Avoid): - Beta‑blockers: may mask the adrenergic signs of hypoglycemia. - MAO inhibitors: can potentiate insulin‑induced hypoglycemia.

Moderate Interactions (Monitor Closely): - Oral hypoglycemics (e.g., sulfonylureas, meglitinides): additive glucose‑lowering effect may increase hypoglycemia risk. - Thiazide diuretics: may raise blood glucose levels, requiring dose adjustment. - Corticosteroids: can reduce insulin efficacy, necessitating closer monitoring.